Strategic Blueprint LLC Has $2.75 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Strategic Blueprint LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,861 shares of the biopharmaceutical company’s stock after selling 226 shares during the quarter. Strategic Blueprint LLC’s holdings in Regeneron Pharmaceuticals were worth $2,750,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $49,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Citigroup lowered their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday. Sanford C. Bernstein dropped their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $689.31 on Wednesday. The firm’s fifty day moving average price is $724.48 and its two-hundred day moving average price is $930.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $75.75 billion, a P/E ratio of 17.06, a P/E/G ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.